Healthcare Industry News: Alzheimer’s disease
News Release - February 8, 2011
Positron’s Attrius(R) PET Scanner Seeks Market Expansion into Neurologic ImagingAdditional Market Opportunity in Eli Lilly’s New Alzheimer's Disease Imaging Agent
INDIANAPOLIS--(Healthcare Sales & Marketing Network)-- Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on nuclear cardiology, announced today that with the conditional U.S. Food and Drug Administration (FDA) approval of Eli Lilly’s PET imaging agent Amyvid (florbetapir), it expects to see an expanded market opportunity for its Attrius® PET scanner.
On January 20th, an advisory committee of the FDA voted to conditionally recommend approval of Eli Lilly's PET imaging agent Amyvid for detecting beta amyloid plaque deposits that could be precursors to Alzheimer's disease.
“Positron's Attrius® PET system is an ideal choice for brain imaging due to its small footprint and cost effective pricing, all without the need of traditional CT imaging. The approval of this new neurologic agent should afford a large market opportunity for our Attrius® PET scanner. Positron’s current product offerings will be expanded to include this new neurologic market segment; we will continue to identify additional applications for our Attrius® PET scanner,” said Patrick G. Rooney, chief executive officer of Positron.
According to the Alzheimer’s Association it is currently estimated that approximately five million Americans are affected by Alzheimer’s disease. Alzheimer’s disease is defined by the accumulation of beta-amyloid in the brain in form of plaques, and is thought to be caused by this accumulation. Eli Lilly’s product will have the ability to detect amyloid plaque and the future commercial availability of an anti-amyloid therapeutic agent will create a clinical need to identify Alzheimer’s disease patients with beta-amyloid.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius®, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
Source: Positron Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.